Annexon (ANNX) Return on Capital Employed (2020 - 2026)
Annexon (ANNX) posted quarterly Return on Capital Employed of 87.52% for Q1 2026, down 2510.0% year-over-year from 3.63% in Q1 2025, and up 14.78% quarter-over-quarter from 102.7% in Q4 2025.
Annexon (ANNX) Return on Capital Employed (2020 - 2026) Analysis & Trends
Annexon's Return on Capital Employed history runs 7 years deep, the most recent figure standing at 87.52% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 2510.0% year-over-year to 87.52%; the TTM figure through Mar 2026 stood at 87.52% (down 2510.0% YoY), while the FY2025 annual figure was 79.8%, down 2728.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 87.52%, up from 102.7% in the prior quarter.
- The five-year high for Return on Capital Employed was 35.34% in Q3 2024, with the low at 107.55% in Q3 2025.
- The 5-year median for Return on Capital Employed is 61.73% (2023), against an average of 64.94%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed jumped 3940 bps in 2024, then tumbled 7221 bps in 2025.
- Annexon's Return on Capital Employed stood at 52.65% in 2022, then fell by 17 bps to 61.73% in 2023, then climbed by 25 bps to 46.14% in 2024, then plunged by 123 bps to 102.7% in 2025, then increased by 15 bps to 87.52% in 2026.
- Business Quant data shows ANNX's Return on Capital Employed at 87.52% in Q1 2026, 102.7% in Q4 2025, and 107.55% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - | -97.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -97.48% |
| Mar 31, 2026 | -87.52% |
| Dec 31, 2025 | -102.70% |
| Sep 30, 2025 | -107.55% |
| Jun 30, 2025 | -82.68% |
| Mar 31, 2025 | -62.42% |
| Dec 31, 2024 | -46.14% |
| Sep 30, 2024 | -35.34% |
| Jun 30, 2024 | -37.56% |
| Mar 31, 2024 | -45.55% |
| Dec 31, 2023 | -61.73% |
| Sep 30, 2023 | -74.74% |
| Jun 30, 2023 | -65.10% |
| Mar 31, 2023 | -59.61% |
| Dec 31, 2022 | -52.65% |
| Sep 30, 2022 | -59.38% |
| Jun 30, 2022 | -67.77% |
| Mar 31, 2022 | -55.59% |
| Dec 31, 2021 | -47.21% |
| Sep 30, 2021 | -37.68% |